121 related articles for article (PubMed ID: 17115486)
21. Gabapentin and tinnitus relief.
Shulman A
Int Tinnitus J; 2008; 14(1):1-5. PubMed ID: 18616079
[No Abstract] [Full Text] [Related]
22. [Gabapentin in the treatment of ocular neuromyotonia].
Porta-Etessam J; Parejo-Carbonell B; Gómez-Vicente L; Marcos-De Vega MA
Rev Neurol; 2009 Mar 16-31; 48(6):332-3. PubMed ID: 19291663
[No Abstract] [Full Text] [Related]
23. Safeguarding patient welfare: who's in charge?
Henney JE
Ann Intern Med; 2006 Aug; 145(4):305-7. PubMed ID: 16908923
[No Abstract] [Full Text] [Related]
24. Long-term effect of gabapentin in stiff limb syndrome: a case report.
Holmøy T
Eur Neurol; 2007; 58(4):251-2. PubMed ID: 17851249
[No Abstract] [Full Text] [Related]
25. FDA approved new drug bulletin. Gabapentin (neurontin).
RN; 1994 Jul; 57(7):39-40. PubMed ID: 8047795
[No Abstract] [Full Text] [Related]
26. Therapeutic freedom.
Trout ME
J Leg Med (N Y); 1974; 2(5):40-2. PubMed ID: 4548704
[No Abstract] [Full Text] [Related]
27. Be wary of recommending off-label use of meds.
Luttrull S
Adv Nurse Pract; 2001 Feb; 9(2):18. PubMed ID: 12416047
[No Abstract] [Full Text] [Related]
28. Tremors: learning to stop the shakes.
Struble LM
Nurse Pract; 2010 Jun; 35(6):18-25; quiz 25-6. PubMed ID: 20479624
[No Abstract] [Full Text] [Related]
29. Off-label drugs: question your doctor.
Consum Rep; 2007 Jun; 72(6):47. PubMed ID: 17632948
[No Abstract] [Full Text] [Related]
30. Gabapentin for pain: balancing benefit and harm.
Ebell M; Kripke C
Am Fam Physician; 2006 Feb; 73(3):435. PubMed ID: 16477890
[No Abstract] [Full Text] [Related]
31. Pfizer to pay $430 million over promoting drug to doctors.
Harris G
N Y Times Web; 2004 May; ():C6. PubMed ID: 15290803
[No Abstract] [Full Text] [Related]
32. [Neuropathic pain in children].
Fournier-Charrière E
Arch Pediatr; 2010 Jun; 17(6):665-6. PubMed ID: 20654832
[No Abstract] [Full Text] [Related]
33. Refractory hiccup: successful treatment with gabapentin.
Alonso-Navarro H; Rubio L; Jiménez-Jiménez FJ
Clin Neuropharmacol; 2007; 30(3):186-7. PubMed ID: 17545753
[TBL] [Abstract][Full Text] [Related]
34. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
35. Drug promotion.
Kalish RS
N Engl J Med; 1995 Apr; 332(15):1032; author reply 1033. PubMed ID: 7794341
[No Abstract] [Full Text] [Related]
36. Disseminating findings from a drug class review: using best practices to inform prescription of antiepileptic drugs for bipolar disorder.
Melvin CL; Ranney LM; Carey TS; Evans WD; AED Dissemination Panel ; Kreps G; Linden T; Oldham J
J Psychiatr Pract; 2008 Mar; 14 Suppl 1():44-56. PubMed ID: 19034209
[TBL] [Abstract][Full Text] [Related]
37. Prescriptions: how your doctor makes the choice.
Shapiro JP; Schultz S
US News World Rep; 2001 Feb; 130(7):58-61. PubMed ID: 11225095
[No Abstract] [Full Text] [Related]
38. Severe protracted alcohol withdrawal syndrome: prevalence and pharmacological treatment at an inpatient detoxification unit--a naturalistic study.
Bonnet U; Specka M; Hamzavi Abedi R; Wiltfang J; Scherbaum N
Pharmacopsychiatry; 2009 Mar; 42(2):76-8. PubMed ID: 19308884
[No Abstract] [Full Text] [Related]
39. Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease.
Paliwal VK; Gupta PK; Pradhan S
Neurol India; 2010; 58(5):761-3. PubMed ID: 21045506
[TBL] [Abstract][Full Text] [Related]
40. Pfizer versus Kaiser: insurers want their day in court.
Silverman E
BMJ; 2013 Jun; 346():f3738. PubMed ID: 23760967
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
